Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in those with multiple melanoma. “I-131-CLR1404…

Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has applied to the U.S. Food & Drug Administration to begin a clinical study of a highly-selective,…

Cellectar Biosciences announced Wednesday that Acting CEO Simon Pedder, PhD., has been promoted to president and CEO. Dr. Pedder began his new role on Tuesday. “I am … appreciative of…